ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...

Professor Zhaohui Tang and Associate Professor Zhilin Liu from the team of Professor Xuesi Chen at the Changchun Institute of ...

The "In Situ Hybridization Market Report by Product, Technique, Application, End User, Countries and Company Analysis ...

Professor Zhaohui Tang and Associate Professor Zhilin Liu from the team of Professor Xuesi Chen at the Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, developed ...

Professor Zhaohui Tang and Associate Professor Zhilin Liu from the team of Professor Xuesi Chen at the Changchun Institute of Applied Chemistry ...

Some tumours are cancerous, but not all cancers can form tumours. How are cancers different from the abnormal pumps you ...

The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar® (TLD-1433) in patients with Bacillus ...

Within tumors in the human body, there are immune cells (macrophages) capable of fighting cancer, but they have been unable ...

An update from the phase 2 LEGEND trial shows that the investigational nonviral gene therapy detalimogene voraplasmid has achieved a 62% complete response rate at six months in patients with high-risk ...

Breast cancer survivors with dense breast tissue should be proactive in their screening approach, considering both 3D ...

January 12, 2026. Infinitusbio.AI, a U.S.-based Pharmatech company and creator of the proprietary Simulative AI Digital Cell Clone platform, and Oncovita, a Paris-based biotechnology company spun out ...